scispace - formally typeset
W

Wolfram Ruf

Researcher at University of Mainz

Publications -  316
Citations -  18710

Wolfram Ruf is an academic researcher from University of Mainz. The author has contributed to research in topics: Tissue factor & Signal transduction. The author has an hindex of 75, co-authored 295 publications receiving 17157 citations. Previous affiliations of Wolfram Ruf include Scripps Research Institute & Washington University in St. Louis.

Papers
More filters
Journal ArticleDOI

Activation of Endothelial Cell Protease Activated Receptor 1 by the Protein C Pathway

TL;DR: The prototypical thrombin receptor is the target for EPCR-dependent APC signaling, suggesting a role for this receptor cascade in protection from sepsis.
Journal ArticleDOI

The structural biology of expression and function of tissue factor.

TL;DR: Analysis of the structural biology of TF provides insights into the both the expression of the gene and the function of this cell surface receptor in the initiation of the coagulation protease cascades.
Journal Article

Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody.

TL;DR: This study reports that 500 micrograms/kg of either immunoglobulin G (IgG) or Fab fragments of a monoclonal antibody against TF administered to baboons as a pretreatment attenuates the coagulopathy and protects against LD100 Escherichia coli.
Journal ArticleDOI

Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis.

TL;DR: Cell surface expression of functional TF contributes to melanoma progression by allowing metastatic cells to provide requisite signals for prolonged adhesive interactions and/or transmigration of tumor cells across the endothelium, resulting in successful metastatic tumor implantation.
Journal ArticleDOI

Regulation of angiogenesis by tissue factor cytoplasmic domain signaling

TL;DR: It is shown that the tissue factor (TF)-VIIa protease complex, independent of triggering coagulation, can promote tumor and developmental angiogenesis through protease-activated receptor-2 (PAR-2) signaling, and targeting the TF-VIIa signaling pathway may enhance the efficacy of angiostatic treatments for cancer and neovascular eye diseases.